SCHEMBL3624335

SCHEMBL3624335

C=CC(O)Nc1ccccc1C=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.43
▸ LMNA P02545 2/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ THRB P10828 1/20 0.43
▸ BLM P54132 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ TRIM24 O15164 1/20 0.41
▸ TRIM33 Q9UPN9 1/20 0.41
▸ CYP2C9 P11712 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ ALDH1A1 P00352 3/20 0.36
▸ TSHR P16473 1/20 0.36
▸ ERN1 O75460 3/20 0.34
▸ ELANE P08246 1/20 0.33
▸ PRTN3 P24158 1/20 0.33
▸ SRC P12931 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ PTGDR2 Q9Y5Y4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5490434 0.78 LMNA (0.43) KMT2ALMNAMEN1THRBBLM
SCHEMBL11875527 0.76 CYP2C9 (0.41) KMT2ALMNAMEN1THRBBLM
SCHEMBL20206272 0.76 NPC1 (0.42) LMNATDP1ALDH1A1HPGDHTT
SCHEMBL4790891 0.73 MEN1 (0.49) KMT2AMEN1TDP1CYP2C9CYP2C19
SCHEMBL964992 0.72 LMNA (0.50) KMT2ALMNAMEN1THRBBLM
SCHEMBL3626947 0.71 L3MBTL1 (0.43) KMT2ALMNAMEN1TDP1ALDH1A1
SCHEMBL7122669 0.71 MAPT (0.54) KMT2ALMNAMEN1BLMTDP1
SCHEMBL7033768 0.71 LMNA (0.55) KMT2ALMNAMEN1THRBBLM
SCHEMBL1325378 0.71 LMNA (0.48) KMT2ALMNAMEN1THRBBLM
Hydrochloric Acid SCHEMBL7804693 0.71 LMNA (0.48) KMT2ALMNAMEN1THRBBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6998489-B2 Methods of making indazoles ALCON, INC. (CH) 2006-02-14 — — US claimed
EP-1392659-A4 METHODS OF MAKING INDAZOLES ALCON INC (CH) 2004-10-20 — — EP claimed
US-20040142998-A1 Methods of making indazoles ALCON, INC. (CH) 2004-07-22 — — US claimed
EP-1392659-A1 METHODS OF MAKING INDAZOLES Alcon, Inc. (CH) 2004-03-03 — — EP claimed
WO-2002098862-A1 METHODS OF MAKING INDAZOLES ALCON, INC. (CH) 2002-12-12 — — WO claimed
US-7799930-B2 1-alkyl-3-aminoindazoles ALCON, INC. (CH) 2010-09-21 — — US disclosed
US-20090149659-A1 1-ALKYL-3-AMINOINDAZOLES ALCON, INC. (CH) 2009-06-11 — — US disclosed
EP-1578729-A4 1-ALKYL-3-AMINOINDAZOLES ALCON INC (CH) 2007-08-29 — — EP disclosed
US-20060052613-A1 1-alkyl-3-aminoindazoles ALCON, INC. (CH) 2006-03-09 — — US disclosed
US-6998489-B2 Methods of making indazoles ALCON, INC. (CH) 2006-02-14 — — US disclosed
EP-1578729-A1 1-ALKYL-3-AMINOINDAZOLES Alcon, Inc. (CH) 2005-09-28 — — EP disclosed
EP-1392659-A4 METHODS OF MAKING INDAZOLES ALCON INC (CH) 2004-10-20 — — EP disclosed
WO-2004058725-A1 1-ALKYL-3-AMINOINDAZOLES ALCON, INC. (CH) 2004-07-15 — — WO disclosed
EP-1392659-A1 METHODS OF MAKING INDAZOLES Alcon, Inc. (CH) 2004-03-03 — — EP disclosed
WO-2002098862-A1 METHODS OF MAKING INDAZOLES ALCON, INC. (CH) 2002-12-12 — — WO disclosed
US-5408021-A Used in the fabrication of polymeric films for second order nonlinear optics E. I. DU PONT DE NEMOURS AND COMPANY (US) 1995-04-18 — — US disclosed
EP-0560909-B1 POLYMERIC FILMS FOR SECOND ORDER NONLINEAR OPTICS DU PONT (US) 1994-11-23 — — EP disclosed
US-5294493-A Multilayer E. I. DU PONT DE NEMOURS AND COMPANY (US) 1994-03-15 — — US disclosed
EP-0560909-A1 POLYMERIC FILMS FOR SECOND ORDER NONLINEAR OPTICS. DU PONT (US) 1993-09-22 — — EP disclosed
WO-1992010781-A1 POLYMERIC FILMS FOR SECOND ORDER NONLINEAR OPTICS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1992-06-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052613-A1 1-alkyl-3-aminoindazoles NAT1, AADAC, CYP1B1 KMT2A 2297/4885LMNA 1795/4885MEN1 1175/4885
US-20040142998-A1 Methods of making indazoles NAT1, CYP3A5, ALDH3A1 KMT2A 2228/4885LMNA 3826/4885MEN1 3316/4885
US-20090149659-A1 1-ALKYL-3-AMINOINDAZOLES NAT1, AADAC, CYP1B1 KMT2A 2297/4885LMNA 1795/4885MEN1 1175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback